Fig. 2: Prevalence rates of various tumor types. | Modern Pathology

Fig. 2: Prevalence rates of various tumor types.

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Fig. 2

a Shows all the prevalence rates based on the CDx cutoffs: DAKO 22C3 assay and tumor proportion scoring (TPS) method were used for NSCLC with a TPS cutoff of 1; DAKO 22C3 assay with combined positive scoring (CPS) method were used for gastric or gastroesophageal junction adenocarcinoma, cervical cancer, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), and esophageal squamous cell carcinoma with a CDx cutoff of CPS ≥ 1%, CPS ≥ 1%, CPS ≥ 10%, CPS ≥ 1%, and CPS ≥ 10%, respectively; and SP142 CDx assay with tumor-infiltrating immune cell (IC) scoring method was used for breast carcinoma cases. b Shows the prevalence of all the tumor types without a CDx cutoff (except for NSCLC which has a CDx). DAKO 22C3 with the TPS scoring method was used for these cases and the results were stratified into a negative (<1%), low positive (1–49%), or high positive (≥50%) category for all the exploratory indications.

Back to article page